Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer.

"Declarations Ethics approval and consent to participate: Not applicable.Consent for publication: Not applicable.Author contributions:Mark Pegram: Conceptualization; Formal analysis; Writing – review & editing.Richard Pietras: Conceptualization; Formal analysis; Writing – review & editing.Chau T. Dang: Conceptualization; Formal analysis; Writing – review & editing.Rashmi Murthy: Conceptualization; Formal analysis; Writing – review & editing.Thomas Bachelot: Conceptualization; Formal analysis; Writing – review & editing.Wolfgang Janni: Conceptualization; Formal analysis; Writing – review & editing.Priyanka Sharma: Conceptualization; Formal analysis; Writing – review & editing.Erika Hamilton: Conceptualization; Formal analysis; Writing – review & editing.Cristina Saura: Conceptualization; Formal analysis; Writing – review & editing.Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was sponsored by Pfizer Inc.Competing interests:Mark Pegram has nothing to disclose.Richard Pietras reports previous participation as a consultant for Pfizer, Roche, Genentech, AstraZeneca, Eli Lilly, and Enlibrium.Chau T. Dang has nothing to disclose.Rashmi Murthy has nothing to disclose.Thomas Bachelot reports personal fees from Seagen, Pfizer, AstraZeneca/Daiichi Sankyo, Novartis, and Eli Lilly. Institutional financial interests (paid directly to his institution) include Seagen, Pfizer Inc, AstraZeneca/Daiichi, and Novartis, and non-financial support from Pfizer Inc outside the submitted work.Wolfgang Janni has nothing to disclose.Priyanka Sharma reports receiving consulting fees and/or honoraria from the following: Pfizer, Merck, Gilead, Seattle Genetics, Novartis, AstraZeneca, GSK; research support to the institution: Novartis, Bristol Meyers Squibb, Merck, Gilead.Erika Hamilton has nothing to disclose.Cristina Saura has served as a consultant, participated in advisory boards, served as an expert witness, or served on a steering committee for AstraZeneca, AX’s Consulting SARL, Boehringer Ingelheim, Bristol Meyers Squibb, Byondis B.V., Daiichi Sankyo, Eisai Europe Ltd., Exeter Pharma, LLC, F. Genentech, German Breast Group, Gilead, GlaxoSmithKline, Inditex, InnoUp Farma, Lilly SAU, International Breast Cancer Study Group (IBCSG), Macrogenics, MediTech, Medsir, Menarini, Merck Sharp & Dohme España, Merus, Millenium, Netherlands Cancer Institute (NKI), Novartis, Pfizer Inc, Philips Health Works, Pierre Fabre, Puma Biotechnology Inc, Roche Farma, SA, SACE Medhealth SL, Sanofi, SeaGen Int., Simon Kucher & Partners SL, Solti, Synthon Biopharmaceuticals BV, Queen Mary (University of London), and Zymeworks.Availability of data and materials: Not applicable. Competing interests: Mark Pegram has nothing to disclose."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was sponsored by Pfizer Inc."